Are there alternative GLP-1s with fewer gastrointestinal side effects
doi: 10.1038/s41591-022-02026-4 Summary Keywords obesity, molecular mechanism, semaglutide, liraglutide, weight loss Citation Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramrez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D and Zambrano AK (2024) Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial Metab Target Organ Damage
Published July 17 in the Journal of the American Heart Association , researchers at Northwestern University analyzed data from the Medical Expenditure Panel Survey, reviewing nearly 1,900 participants who reported using a GLP-1 medication between 2017 and 2022
The Peptide Interaction Checker cross-references peptide combinations against documented interactions and side effect overlap
